首页> 外文期刊>Surgery >P38 mitogen-activated protein kinase inhibition attenuates ischemia-reperfusion injury of the rat liver.
【24h】

P38 mitogen-activated protein kinase inhibition attenuates ischemia-reperfusion injury of the rat liver.

机译:P38丝裂原激活的蛋白激酶抑制作用减弱了大鼠肝脏的缺血再灌注损伤。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Several studies have implicated the mitogen-activated protein kinase (MAPK) signal pathway in non-hepatic organ ischemia-reperfusion injury. However, the role of p38 MAPK in hepatic ischemia-reperfusion injury remains unclear. This study investigated the role of p38 MAPK in hepatic ischemia-reperfusion injury. METHODS: Male Sprague-Dawley rats were divided into 4 groups (sham, FR-only, control, and FR-treated groups). The animals in the control and FR-treated groups were subjected to 30 minutes of warm ischemia with congestion of the gut. The FR-only and FR-treated groups received FR167653 (FR), which is a novel p38 MAPK inhibitor. The serum levels of aspartate transaminase, alanine transaminase, lactate dehydrogenase, tumor necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta) were measured (each, n = 6). Liver tissue blood flow was measured at pre-ischemia, end-ischemia, and 30, 60, 90, and 120 minutes after reperfusion (each, n = 4). The liver tissues in the control and FR-treated groups were excised for p38 MAPK and c-Jun N-terminal kinase (JNK) analyses and histopathology (each, n = 4). RESULTS: Serum levels of aspartate transaminase, alanine transaminase, lactate dehydrogenase, TNF-alpha, and IL-1beta were significantly lower in the FR-treated group than in the control group, and liver tissue blood flow was significantly higher in the FR-treated group than in the control group. Histopathologically, tissue damage was milder in the FR-treated group than in the control group. Both p38 MAPK and JNK were markedly phosphorylated after 30 minutes of reperfusion, and FR inhibited the phosphorylation of p38 MAPK without affecting the JNK. CONCLUSIONS: FR decreased serum TNF-alpha and IL-1beta levels and liver injury associated with the inhibition of p38 MAPK activation. These results suggest that inhibiting the activation of p38 MAPK may attenuate warm ischemia-reperfusion injury of the liver.
机译:背景:几项研究已暗示有丝分裂原活化蛋白激酶(MAPK)信号通路在非肝器官缺血-再灌注损伤中。但是,p38 MAPK在肝缺血再灌注损伤中的作用仍不清楚。这项研究调查了p38 MAPK在肝缺血再灌注损伤中的作用。方法:雄性Sprague-Dawley大鼠分为4组(假,单纯FR,对照组和FR治疗组)。对照组和FR治疗组的动物经历30分钟的热缺血,肠道充血。仅FR和FR治疗组接受FR167653(FR),这是一种新型的p38 MAPK抑制剂。测量血清中的天冬氨酸转氨酶,丙氨酸转氨酶,乳酸脱氢酶,肿瘤坏死因子-α(TNF-α)和白介素-1β(IL-1β)的水平(每组n = 6)。在缺血前,缺血末以及再灌注后30、60、90和120分钟(每个n = 4)测量肝组织的血流量。切除对照组和FR治疗组的肝组织,进行p38 MAPK和c-Jun N末端激酶(JNK)分析和组织病理学检查(每组n = 4)。结果:FR治疗组的血清天冬氨酸转氨酶,丙氨酸转氨酶,乳酸脱氢酶,TNF-α和IL-1β水平显着低于对照组,而FR治疗组的肝组织血流量显着高于对照组。组比对照组。在组织病理学上,FR治疗组的组织损伤较对照组轻。再灌注30分钟后,p38 MAPK和JNK均显着磷酸化,FR抑制p38 MAPK的磷酸化而不影响JNK。结论:FR降低了血清TNF-α和IL-1beta的水平以及肝损伤与p38 MAPK激活的抑制有关。这些结果表明,抑制p38 MAPK的激活可能会减轻肝脏的温暖缺血-再灌注损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号